8-K: Strive Details Semler Scientific Merger Financials & Risks

Strive, Inc. filed an 8-K providing pro forma financial statements and supplementary risk factors for its pending all-stock acquisition of Semler Scientific, Inc.

Summary

• Strive, Inc. is proceeding with an all-stock acquisition of Semler Scientific, Inc., as per the Merger Agreement dated September 22, 2025.
• Both Strive's and Semler Scientific's boards of directors unanimously approved the Merger Agreement on September 21, 2025.
• Each share of Semler Scientific common stock will be converted into 21.05 shares of Strive Class A common stock.
• The filing includes historical financial statements of Semler Scientific, unaudited pro forma combined consolidated financial information, and supplementary risk factors related to the merger.
• Strive is deemed the accounting acquirer, with its existing stockholders expected to hold the greatest voting interest and its senior management controlling the combined entity's strategic direction.
• The estimated purchase price consideration for Semler Scientific is $1,441,536,300, based on 335,241,000 shares of Strive Class A common stock at $4.30 per share.
• The pro forma combined entity reported a net loss of $(17,386,666) for the six months ended June 30, 2025, and $(12,851,934) for the year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The filing provides comprehensive details for a previously announced merger, including pro forma financials and extensive risk factors. While management anticipates future EPS accretion, the pro forma financials show current losses, and the document highlights numerous significant risks associated with the merger and integration, balancing the overall sentiment towards neutral to slightly positive due to the strategic intent.

Positives

• The merger was unanimously approved by the boards of directors of both Strive and Semler Scientific.
• Strive anticipates the merger will be accretive to its forecasted earnings per share on a standalone basis, starting in the first full calendar year after closing.
• Semler Scientific also anticipates the merger will be accretive to its forecasted earnings per share on a standalone basis, starting in the first full calendar year after closing.
• Strive's existing stockholders are expected to have the greatest voting interest in the combined entity.
• Strive's senior management is expected to control the strategic direction of the combined company.

Negatives

• The unaudited pro forma combined consolidated financial statements show a net loss of $(17,386,666) for the six months ended June 30, 2025, and $(12,851,934) for the year ended December 31, 2024.
• Significant transaction costs are expected to be incurred by both Strive and Semler Scientific, which may not be offset by anticipated benefits in the near term.
• The merger may cause dilution to Strive's or Semler Scientific's earnings per share, potentially affecting market prices.
• The integration of the two companies may be more difficult, time-consuming, or costly than expected.
• Management's attention may be diverted from ongoing business operations due to the merger.
• Uncertainty regarding the merger may negatively impact the ability to attract and retain key personnel.
• Contractual restrictions in the Merger Agreement limit Strive's and Semler Scientific's ability to pursue certain transactions or actions prior to closing.

Risks

• Failure to complete the merger or significant delays due to unfulfilled closing conditions, including Semler Scientific stockholder approval and antitrust clearance.
• Governmental or regulatory agencies may seek to block or challenge the merger or impose burdensome conditions.
• The special meetings for stockholder approval may occur before antitrust clearance, potentially leading to decisions without full knowledge of conditions.
• Failure to realize anticipated benefits, including cost savings and strategic gains, or the occurrence of additional expenses.
• Integration of the two companies may be more difficult, time-consuming, or costly than expected.
• Diversion of management's attention from ongoing business operations and opportunities.
• Dilution caused by Strive's issuance of additional shares of its Class A common stock.
• Potential adverse reactions from customers or changes to business or employee relationships.
• Changes in Strive's or Semler Scientific's share price before closing.
• The Merger Agreement contains provisions limiting Strive's and Semler Scientific's ability to pursue alternative transactions, including a potential $49 million termination fee payable by Semler Scientific to Strive.
• Business uncertainties during the pendency of the merger may cause third parties to delay or defer decisions.
• Difficulty in attracting and retaining key personnel due to uncertainty about future roles.
• Market prices of Strive and Semler Scientific common stock may fluctuate significantly while the merger is pending and after completion.
• Strive is subject to contractual restrictions that may hinder its operations, and Semler Scientific's restrictions may not prevent actions adverse to Strive.
• Unaudited pro forma financial information is illustrative and may not be representative of actual combined results.
• Stockholder litigation could prevent or delay the closing or negatively impact businesses.
• Future sales and issuance of Strive Class A Common Stock could result in dilution and cause stock prices to fall.
• The combined company may have unknown liabilities.
• There is no guarantee that the combined company will declare and pay dividends following the merger.
• Future disclosures relating to the merger (e.g., Form S-4) may not align with investor expectations.

Future Outlook

Strive and Semler Scientific both anticipate that the merger will be accretive to their respective forecasted earnings per share on a standalone basis, beginning in the first full calendar year after the closing of the transaction.

Management Comments

• Strive currently anticipates that the Merger will be accretive to Strives forecasted earnings per share on a standalone basis, and Semler Scientific currently anticipates that the Merger will be accretive to Semler Scientifics forecasted earnings per share on a standalone basis, in each case beginning in the first full calendar year after closing.
• Strive and Semler Scientific believe that the Merger will receive the necessary antitrust clearance.

Industry Context

This merger signifies a strategic move for Strive, an asset management Bitcoin Treasury Company, to expand its operations by acquiring Semler Scientific. This could indicate a trend of companies leveraging digital asset strategies to drive growth and diversify their business models within the broader financial and healthcare technology sectors. The integration of a medical device company (Semler Scientific) into a Bitcoin-focused asset manager (Strive) suggests a potentially unconventional strategy, aiming to combine stable cash flows or assets with digital asset investments.

Corporate Governance

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company could adversely affect the merger.
• Stockholder litigation could prevent or delay the Closing or otherwise negatively impact each of Strive's and Semler Scientific's businesses and operations.
• Governmental authorities could seek to block or challenge the Merger as they deem necessary or desirable in the public interest.
• A private party could initiate an action under the antitrust laws challenging or seeking to enjoin the Merger, before or after they are completed.

Stakeholder Impact

• Shareholders (Strive & Semler Scientific): Potential for dilution from stock issuance, fluctuations in stock price, and the need for Semler Scientific stockholder approval. Strive shareholders will retain the majority voting interest.
• Employees (Strive & Semler Scientific): Uncertainty about future roles, potential loss of key personnel, and challenges in attraction and retention during the merger pendency.
• Customers (Strive & Semler Scientific): May delay or defer decisions, or seek to change/cancel existing business relationships due to merger uncertainty.
• Creditors: Potential impact from changes in financial position and operational results of the combined company.
• Regulatory Authorities: Involved in antitrust clearance and potential imposition of conditions.

Next Steps

• Semler Scientific stockholders will vote on the approval and adoption of the Merger Agreement.
• Strive intends to file a Registration Statement on Form S-4, including an Information Statement/Proxy Statement/Prospectus, with the SEC.
• Strive and Semler Scientific will seek antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
• The companies will work towards satisfying all customary closing conditions for the merger.
• The final acquisition accounting, including a purchase price allocation analysis, will be completed after the closing of the transaction.

Key Dates

Recommendation

This filing provides supplementary information for a previously announced merger, including pro forma financials and extensive risk factors. While management anticipates future EPS accretion, the pro forma statements show combined losses, and the integration process carries significant risks, including potential delays, unforeseen costs, and management distraction. A seasoned investor would likely maintain a 'hold' position to observe the successful completion of the merger, the integration process, and the realization of anticipated synergies and EPS accretion before making a more definitive investment decision. The information presented is primarily for transparency regarding the merger's implications rather than a catalyst for immediate strong buy or sell action.

Keywords

Strive Inc., Semler Scientific, Merger, Acquisition, 8-K Filing, Pro Forma Financials, Risk Factors, All-Stock Deal, Bitcoin Treasury Company, Asset Management, Corporate Governance, Shareholder Approval, Antitrust Clearance, Financial Reporting